Rapid Micro Biosystems announced a new multi‑system order from Samsung Biologics that expands the use of its Growth Direct platform across Samsung’s manufacturing network. The order follows a record multi‑system placement from Amgen in the fourth quarter of 2025 and signals continued momentum for the company’s flagship system.
In the fourth quarter of 2025, Rapid Micro Biosystems reported revenue of $11.3 million, a 37% year‑over‑year increase from $8.2 million in Q4 2024. The quarter also saw a net loss of $12.5 million and earnings per share of $‑0.28, missing the consensus estimate of $‑0.23. CEO Robert Spignesi noted, "We closed 2025 with significant momentum, delivering 20% year‑over‑year revenue growth. Our performance was highlighted by a record multi‑system order from Amgen in the fourth quarter. This trajectory has continued into 2026, underscored by a meaningful multi‑system order from Samsung Biologics in the first quarter. These milestones demonstrate the accelerating global adoption of the Growth Direct platform as our customers standardize on our technology across their manufacturing networks."
The new Samsung order is a multi‑system placement that will add recurring consumable and service revenue, reinforcing Rapid Micro’s razor‑blade business model. CFO Sean Wirtjes highlighted the company’s system deployment pace, stating, "During the fourth quarter, we placed 16 Growth Direct systems, which was also a record, compared to six systems in the fourth quarter last year." The order expands Samsung’s use of the platform, which is expected to accelerate time‑to‑results, reduce manual labor, and improve data integrity for its biologics and sterile injectables programs.
Looking ahead, Rapid Micro has guided for 2026 revenue of $37 million to $41 million, 30 to 38 system placements, and an approximate 20% gross margin for the full year. The company also plans to launch a next‑generation cloud‑native software platform in the second half of 2026 and is advancing a collaboration with MilliporeSigma that will support additional system placements in Europe and Asia. CEO Spignesi added, "Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and we're pleased to strengthen our partnership with this new multi‑system order. Their integrated plant design embeds advanced automation and digitalization capabilities, including seamless connectivity across operations – to consistently deliver high productivity and quality. The Growth Direct platform enhances that foundation by delivering faster time to results, greater accuracy, and stronger data integrity. We look forward to supporting Samsung as it continues scaling its next‑generation manufacturing operations."
The Samsung order underscores Rapid Micro’s growing commercial traction and its strategy to increase recurring revenue. While the company remains in a net loss for the quarter, the new order and the guidance for 2026 suggest a path toward margin expansion and a higher recurring‑revenue mix, positioning the company for continued growth in the automated microbial quality‑control market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.